Author Correction: Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.

ABSTRACT

Eur Rev Med Pharmacol Sci 2023; 27 (11) 5119-5127-DOI 10.26355/eurrev_202306_32628-PMID 37318485, published online on June 13, 2023. After publication, the authors have found some mistakes. This erratum corrects the following In Figure 1, "4 withdrawal" has been corrected into "7 withdrawal" and "95 completed study" has been corrected into "97 corrected study" In the "Efficacy" paragraph at page 5123, "1.0 in the placebo group" has been corrected into "-1.0 in the placebo group". The legend of Table V has been corrected as follows Table V. Published clinical studies of the mucolytic and expectorant efficacy of IV NAC in respiratory diseases. In Table V, the data regarding the Treatment groups (duration) by Grassi et al5 have been corrected as follows NAC oral 200 mg TID NAC IM 300 mg BID NAC IV 500 mg OD (6 days) In Table V, the data regarding the Treatment groups (duration) by Henneghien et al8 have been corrected as follows NAC oral 200 mg TID NAC IV 300 mg TID (3-10 days) NAC IV 500 mg BID (12 days) There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https//www.europeanreview.org/article/32628.